Physician profile
Jarod Ryan Cates
NPI 1619939972
$1,046.11
in general payments reported to CMS, 2019-2025
20 companies · $351 in 2025
The $351 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $83.89 · 2023: $175 · 2024: $155 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $198.35 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Sanofi Pasteur INC. | $132.71 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $129.10 | 2023 | Qelbree |
| Corium, LLC | $120.60 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $117.88 | 2024-2025 | Gardasil 9, Rotateq, Proquad |
| Sanofi-Aventis U.S. LLC | $66.77 | 2024-2025 | |
| Abbvie INC. | $31.26 | 2019 | |
| Shire North American Group INC | $29.55 | 2019 | |
| Cranial Technologies, INC | $29.49 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $28.96 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.43 | 2025 | Caplyta |
| Verrica Pharmaceuticals INC. | $22.77 | 2025 | Ycanth |
| Amgen INC. | $21.57 | 2020 | |
| Exact Sciences Corporation | $18.06 | 2025 | Cologuard Collection Kit |
| Adlon Therapeutics L.P. | $13.83 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.75 | 2020 | |
| Dermira, INC. | $11.75 | 2019 | |
| Novo Nordisk INC | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarod Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.